AKTS (Aktis Oncology) Research & Development: $36.53 Mil (TTM As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.15
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Research & Development?

Aktis Oncology AKTS +8.54% 9 Research & Development is $36.53 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aktis Oncology's Research & Development for the three months ended in Mar. 2026 was $20.04 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $36.53 Mil.

Aktis Oncology  (NAS:AKTS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aktis Oncology Research & Development Related Terms

Aktis Oncology Research & Development Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Research & Development Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
14.30 25.92 40.95 67.45

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial 12.61 15.86 0.00 16.49 20.04
AKTS
9GF Score
Aktis Oncology Inc AKTS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $36.53 Mil mean?
Aktis Oncology (AKTS) has a Research & Development of $36.53 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Research & Development too high?
Aktis Oncology's current Research & Development is $36.53 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Research & Development compare to OLMA and EYPT?
Aktis Oncology's Research & Development of $36.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Research & Development is $36.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Research & Development of $36.53 Mil. The current Research & Development is $36.53 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Research & Development is $36.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.15
Price